BRAIN Biotech AG

EPHORAN Multi-Imaging Solutions is a Contract Research Organization providing imaging expertise and knowledge to study, develop and promote the application of imaging technologies in preclinical drug research and development.

EPHORAN provides the opportunity to apply a translational pharmacological approach in drug R&D, evaluating in animal models a molecular-based proof of biological activity and mechanism of action, and translating it into the clinical setting. All the Techniques extensively employed in the clinical setting(e.g. PET, CT, SPECT, MRI, US and in Optical Imaging, both visible light and Near Infra Red) are available.

EPHORAN fosters the development of diagnostic tools, reagents and methodologies for experimental imaging and makes the drug development faster and more cost effective. Pharmaceutical companies will take advantage from its preclinical imaging technologies to carry on more effectively their R&D projects in different therapeutic such as oncology, cardiovascular and CNS. The application of Imaging techniques allows a significant reduction of the time-to-market of novel compounds. Other users that will benefit from access to Ephoran’s services are Researchers from academic and research institution.

ABS Laboratories is a MHRA, GLP and GCP accredited contract research organisation. We specialise in the quantification of drugs, metabolites and biomarkers in biological fluids using LC-MS/MS, GC-MS, LC-UV and multiplexed biomarker assays.

Our bioanalytical staff are experts in developing, validating and applying sophisticated analytical techniques to achieve the desired out comes all within the regulatory frame work.

ABS prides its self on the quality of its customer service and rapid turn around times. Our skills and state of the art equipment enable us to support a wide range of studies small and large.

We have a wealth of experience supporting Pharmaceutical R&D, Universities and Charitable Organisations from in-vitro research through to preclinical and clinical studies to final MAA/NDA submission. We are also proud to work with the NHS supporting clinical diagnosis, screening and therapeutic drug monitoring.

ABS also owns a large library of validated bioanalytical methods for multiple drugs so is pleased to offer very rapid initialisation and analysis of study samples.

AltraBio is an R&D company for analysis and interpretation of biomedical data in both preclinical and clinical development and for development of analytic and predictive tools. AltraBio is particularly focused on OMICS technologies (genomics, transcriptomics, proteomics etc.) and flow/mass cytometry with the goal of unlocking the value captured in large scale data set generated in life science experimental studies.

AltraBio's work flow covers the part of the R&D process following the generation of data in the experiment. This includes extensive data quality control, normalization, statistical analysis (using nonsupervised and supervised approaches) and their management, visualization and extensive exploration.

In contrast to a pure biostatistics consultancy, AltraBio performs a full-fledged biological interpretation of the analysis results in the context of current biomedical knowledge and generates a report that includes deep bibliography review and biological pathway analysis.

AltraBio applies the state-of-the-art knowledge in biomedicine and bioinformatics to inform both development of informatics tools used in its work and the analysis and interpretation of the experimental data sets.

Also, AltraBio has developed a proprietary tool for the automation of the tedious manual gating in cytometry approaches. This machine learning approach allows the application of a predetermined gating strategy while saving study time/cost and enhancing robustness. The use of this technique is helpful for studies with a high number of samples to treat one by one during a long time or in a batch process and its compatibility with GcLP allows its use in clinical trials.

anacura is an independent analytical centre of excellence in healthcare and drug development. Your go-to provider for top quality laboratory solutions delivered with a great human touch.

AnaBioTec provides analytical solutions (R&D and GMP) for pharma, biopharma, cell & gene therapy developers. Our GMP compliant platform is your reliable partner for end-to end analytical solutions for CMC activities from pre-clinical development, over in all phases of drug development until the lifecycle of commercial products. We deliver analytical techniques for identity, purity, quantity, quality, and potency testing according to the ICH guidelines. Our experts have a proven track record in method development and validation. Our in-house analytical expertise (+ 20 years) in combination with our operational performance helps saving time and shortens time to the market. Complemented with solid advice and effective scientific project management, we anticipate changing priorities and safeguard your milestones and timing.

Labo Nuytinck is specialized in evidence-based laboratory medicine and pathology of human tissue and biological samples. Our priority is to provide physicians with timely and accurate diagnostic support, together with personal advice and expertise in the interpretation of test results to guide therapeutic decisions.

BASF creates chemistry for a sustainable future offering intelligent solutions to the pharmaceutical industry. With its expertise in polymer chemistry, R&D-capabilities and its commitment in developing excipients, BASF creates solutions for Instant & Modified Release, Solubilization, Softgels, Skin-Delivery and Biologics. BASF is the leading supplier of selected APIs such as ibuprofen and omega-3.

About BASF
At BASF, we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. More than 117,000 employees in the BASF Group work on contributing to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio is organized into six segments: Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care and Agricultural Solutions. BASF generated sales of €59 billion in 2019. BASF shares are traded on the stock exchange in Frankfurt (BAS) and as American Depositary Receipts (BASFY) in the U.S. Further information at www.basf.com.

Learn more about how BASF processes personal data at basf.com/data-protection-eu.